Royal Philips announced the launch of Philips BlueControl, a clinically tested wearable medical device that uses blue LED light to reduce symptoms of the skin disease psoriasis vulgaris by 50%.
Philips BlueControl will be introduced to international healthcare professionals at the European Academy of Dermatology & Venereology (EADV) Congress (8 – 12 October) in Amsterdam.
Psoriasis affects around 125 million people worldwide, of which 80% suffer from the most common form, psoriasis vulgaris. This is a condition caused by the overly rapid division of skin cells accompanied by painful inflammation.
Philips conducted two clinical trials in partnership with the University Hospital of Aachen to investigate the efficacy and safety of Philips BlueControl to reduce the symptoms of psoriasis vulgaris. The results showed a 50% reduction on average of symptoms according to the Local Psoriasis Area Severity Index (PASI). No negative side-effects of the blue LED light treatment were observed.
Philips BlueControl has been developed to be easily integrated into a patient’s daily routine and reduces the need for physician’s visits. Worn simply by adjusting a strap on affected arms, legs, elbows and knees, the UV-free blue LED light therapy is enabled by 40 high-intensity blue LEDs with tailored light settings. BlueControl will be prescribed by physicians and available through distributors in The Netherlands, Germany and The UK from October 2014.